Targeting sensitized nerves to treat chronic & debilitating neurogenic disorders
MERCK & CO., INC
Kenilworth, NJ, USA
Effective July 27th, Afferent Pharmaceuticals is now a wholly owned subsidiary of Merck @ Co., Inc., Kenilworth, NJ, USA
(known as MSD outside the United States and Canada)
Afferent Pharmaceuticals, Inc. is a leader in the development of novel, selective drugs for the treatment of a range of debilitating neurogenic disorders.
Afferent is developing a number of selective P2X3 antagonists to treat a broad range of debilitating and highly prevalent neurogenic disorders.